ECSP21004787A - Inhibidores de inflamasoma nlrp3 - Google Patents

Inhibidores de inflamasoma nlrp3

Info

Publication number
ECSP21004787A
ECSP21004787A ECSENADI20214787A ECDI202104787A ECSP21004787A EC SP21004787 A ECSP21004787 A EC SP21004787A EC SENADI20214787 A ECSENADI20214787 A EC SENADI20214787A EC DI202104787 A ECDI202104787 A EC DI202104787A EC SP21004787 A ECSP21004787 A EC SP21004787A
Authority
EC
Ecuador
Prior art keywords
nlrp3
inflamasome
inhibitors
relates
thienopyrrolotriazineacetamide
Prior art date
Application number
ECSENADI20214787A
Other languages
English (en)
Inventor
Juraj Velcicky
Nikolaus Johannes Stiefl
Henri Mattes
Christopher Farady
Angela Mackay
Nina Gommermann
Philipp Janser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21004787A publication Critical patent/ECSP21004787A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de tienopirrolotriazinacetamida de la fórmula (I): (I), en donde R1, R2 y R3 se definen en el presente documento, que inhiben la actividad inflamatoria de la proteína 3 receptora de tipo NOD (NLRP3). La invención se refiere, además, a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
ECSENADI20214787A 2018-07-25 2021-01-22 Inhibidores de inflamasoma nlrp3 ECSP21004787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18185580 2018-07-25
EP19175246 2019-05-17

Publications (1)

Publication Number Publication Date
ECSP21004787A true ECSP21004787A (es) 2021-03-31

Family

ID=67989037

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20214787A ECSP21004787A (es) 2018-07-25 2021-01-22 Inhibidores de inflamasoma nlrp3

Country Status (22)

Country Link
US (1) US12168012B2 (es)
EP (1) EP3827008B1 (es)
JP (1) JP7555327B2 (es)
KR (1) KR20210038877A (es)
CN (1) CN112424207B (es)
AU (1) AU2019309727B2 (es)
BR (1) BR112021000964A2 (es)
CA (1) CA3103943A1 (es)
CL (1) CL2021000191A1 (es)
CO (1) CO2021000537A2 (es)
CR (1) CR20210045A (es)
CU (1) CU20210009A7 (es)
DO (1) DOP2021000019A (es)
EC (1) ECSP21004787A (es)
IL (1) IL280336A (es)
JO (1) JOP20210017A1 (es)
MA (1) MA53388A (es)
MX (1) MX2021000925A (es)
PE (1) PE20210406A1 (es)
PH (1) PH12021550166A1 (es)
SG (1) SG11202012321PA (es)
WO (1) WO2020021447A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126015A4 (en) * 2020-03-31 2024-04-24 Olatec Therapeutics, Inc. METHODS FOR PREVENTING OR TREATMENT OF LUNG INFECTIONS AND PNEUMONIA
MX2022012896A (es) 2020-04-15 2022-11-09 Janssen Pharmaceutica Nv Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3.
CA3174837A1 (en) * 2020-04-15 2021-10-21 Daniel Oehlrich Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway
US20230203064A1 (en) 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3
KR20230005320A (ko) * 2020-04-30 2023-01-09 얀센 파마슈티카 엔.브이. 신규 트리아지노인돌 화합물
AU2021279305A1 (en) * 2020-05-28 2023-02-09 Janssen Pharmaceutica Nv Compounds
CA3178361A1 (en) 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
EP4196125A4 (en) * 2020-08-14 2024-09-04 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
EP3974415A1 (en) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nlrp3 modulators
CA3189887A1 (en) * 2020-09-24 2022-03-31 Daniel Oehlrich New compounds
CN114478537B (zh) * 2020-11-13 2024-02-02 上海拓界生物医药科技有限公司 环酰胺并环化合物及其医药用途
CA3202544A1 (en) * 2020-11-20 2022-05-27 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2022184842A1 (en) 2021-03-04 2022-09-09 Janssen Pharmaceutica Nv 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3
MX2023010223A (es) 2021-03-04 2023-09-11 Janssen Pharmaceutica Nv Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3.
CN113230240B (zh) * 2021-03-22 2022-12-27 广州医科大学 1,3-二苯基丙-2-烯-1-酮衍生物及其应用
CA3215235A1 (en) * 2021-04-13 2022-10-20 Sharon KLIER Methods of treating retinal vasculopathies
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CA3212725A1 (en) * 2021-04-29 2022-11-03 Daniel Oehlrich Phthalazinone derivatives as nlrp3 inflammasome inhibitors
KR20240019083A (ko) 2021-06-04 2024-02-14 에프. 호프만-라 로슈 아게 트리아진 유도체 및 암 치료에서 이의 용도
MX2022007854A (es) 2021-06-23 2022-12-26 Yoda Pharmaceuticals Inc Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3.
WO2023275230A1 (en) 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
CN117940120A (zh) * 2021-07-16 2024-04-26 戴纳立制药公司 化合物、组合物和方法
WO2023028536A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023044043A1 (en) * 2021-09-17 2023-03-23 Denali Therapeutics Inc. Compounds, compositions and methods
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
US20250109126A1 (en) 2021-12-22 2025-04-03 Ac Immune Sa Dihydro-oxazol derivative compounds
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
WO2023158708A1 (en) * 2022-02-16 2023-08-24 Denali Therapeutics Inc. Compounds, compositions, and methods
EP4482841A1 (en) * 2022-02-21 2025-01-01 Sanofi Thienopyrrolotriazine compounds, their preparation and their therapeutic use
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN119998284A (zh) 2022-07-28 2025-05-13 Ac免疫有限公司 新化合物
TW202417456A (zh) * 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
IL319619A (en) 2022-09-23 2025-05-01 Merck Sharp & Dohme Llc Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
KR20250170045A (ko) * 2023-03-17 2025-12-04 벤투스 테라퓨틱스 유에스 인코포레이티드 Nlrp3를 억제하기 위한 아마이드 유도체 및 이의 용도
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
KR20250030934A (ko) 2023-08-25 2025-03-05 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202535370A (zh) 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026024770A1 (en) * 2024-07-23 2026-01-29 New York Blood Center, Inc. Compounds for treatment of hemolysis- and inflammasome-associated diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
WO2011048148A2 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
LT2718270T (lt) 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
BR122022001235B1 (pt) 2011-11-29 2023-04-11 Ono Pharmaceutical Co., Ltd Cristal de cloridrato derivado de purinona
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AU2013312296B2 (en) 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
BR112015012312A2 (pt) 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
SG11201506764WA (en) 2013-04-25 2015-09-29 Beigene Ltd Fused heterocyclic compounds as protein kinase inhibitors
DK3065738T3 (en) 2013-11-05 2018-06-06 Novartis Ag Compositions and Methods for Modulating Farnesoid X Receptors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
KR102368958B1 (ko) 2013-12-20 2022-02-28 노파르티스 아게 Lta4h 억제제로서의 헤테로아릴 부탄산 유도체
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
EP3143026B1 (en) 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
PT3461821T (pt) 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
ES2846776T3 (es) 2014-12-24 2021-07-29 Principia Biopharma Inc Dosificación específica del sitio de un inhibidor de BTK
EP4112618A1 (en) 2015-06-03 2023-01-04 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
RU2018115334A (ru) 2015-10-09 2019-11-11 Ацея Терапьютикс, Инк. Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
LT3371165T (lt) 2015-11-04 2022-05-10 Merck Patent Gmbh Btk inhibitorius, naudojamas vėžiui gydyti
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
RU2728827C2 (ru) 2016-01-05 2020-07-31 Цзянсу Хэнжуй Медицин Ко., Лтд. Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
CA3078195A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds

Also Published As

Publication number Publication date
MA53388A (fr) 2021-06-02
US12168012B2 (en) 2024-12-17
US20210308140A1 (en) 2021-10-07
CL2021000191A1 (es) 2021-08-20
CN112424207A (zh) 2021-02-26
CO2021000537A2 (es) 2021-01-29
DOP2021000019A (es) 2021-02-15
CR20210045A (es) 2021-06-18
KR20210038877A (ko) 2021-04-08
IL280336A (en) 2021-03-01
AU2019309727B2 (en) 2021-12-23
CA3103943A1 (en) 2020-01-30
JP2021532124A (ja) 2021-11-25
BR112021000964A2 (pt) 2021-04-20
CU20210009A7 (es) 2021-08-06
WO2020021447A1 (en) 2020-01-30
MX2021000925A (es) 2021-03-31
CN112424207B (zh) 2024-03-19
EP3827008B1 (en) 2024-07-31
SG11202012321PA (en) 2021-02-25
JP7555327B2 (ja) 2024-09-24
AU2019309727A1 (en) 2021-01-07
JOP20210017A1 (ar) 2021-01-21
PE20210406A1 (es) 2021-03-02
PH12021550166A1 (en) 2021-09-13
EP3827008A1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
PY2019955A (es) Inhibidores de inflamasoma nlrp3
ECSP24014832A (es) Inhibidores de nlrp3
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
CO2024011162A2 (es) Inhibidores de nlrp3
MX2021008426A (es) Nuevos derivados de sulfonilurea sustituida.
DOP2025000013A (es) Inhibidores de inflamasoma nlrp3
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
CO2021001174A2 (es) Inhibidores de ckd8/19
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
UY38133A (es) Nuevos inhibidores de cdk8/19
AR134411A1 (es) Compuestos de uracilo
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos